Posted by Michael Wonder on 06 Jul 2026
Ascelia Pharma provides update on the Orviglance NDA
3 July 2026 - Ascelia Pharma today announced that it has received a complete response letter from the US FDA regarding the Company’s new drug application for Orviglance.
Ascelia will engage with the FDA to find an expedited path forward.
